Candriam S.C.A. Sells 18,155 Shares of Natera, Inc. $NTRA

Key Points

• Candriam S.C.A. reduced its holdings in Natera, Inc. by 15.6%, owning 98,283 shares worth approximately $13.9 million after selling 18,155 shares in the first quarter.
• Several institutional investors, including GDS Wealth Management and Credit Agricole S A, significantly increased their stakes in Natera during the same period, indicating strong interest in the company.
• Natera reported a revenue of $546.6 million for the last quarter, exceeding analyst estimates of $476.84 million, despite a reported loss of ($0.74) earnings per share.

Candriam S.C.A. cut its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 15.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 98,283 shares of the medical research company's stock after selling 18,155 shares during the quarter. Candriam S.C.A. owned approximately 0.07% of Natera worth $13,898,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of NTRA. GDS Wealth Management lifted its holdings in Natera by 325.9% in the 1st quarter. GDS Wealth Management now owns 53,086 shares of the medical research company's stock worth $7,507,000 after buying an additional 40,623 shares during the period. Credit Agricole S A raised its stake in Natera by 60.0% during the first quarter. Credit Agricole S A now owns 35,079 shares of the medical research company's stock valued at $4,961,000 after buying an additional 13,159 shares during the last quarter. Groupama Asset Managment raised its stake in shares of Natera by 48.8% in the first quarter. Groupama Asset Managment now owns 81,839 shares of the medical research company's stock worth $11,780,000 after purchasing an additional 26,841 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Natera by 47.8% in the first quarter. Hsbc Holdings PLC now owns 182,718 shares of the medical research company's stock worth $25,801,000 after acquiring an additional 59,125 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Natera in the first quarter worth $705,000. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Down 1.6%

Shares of NASDAQ:NTRA traded down $2.7120 during mid-day trading on Monday, reaching $162.8880. The stock had a trading volume of 760,205 shares, compared to its average volume of 1,510,139. The company has a market cap of $22.36 billion, a P/E ratio of -85.35 and a beta of 1.76. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The business's 50 day moving average price is $154.85 and its 200 day moving average price is $154.01.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same quarter last year, the company earned ($0.30) earnings per share. The company's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of several recent research reports. UBS Group boosted their price target on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada boosted their price objective on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Stephens restated an "overweight" rating and issued a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research report on Monday, July 28th. Finally, Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. Based on data from MarketBeat, Natera presently has a consensus rating of "Buy" and a consensus target price of $193.19.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the transaction, the insider owned 133,205 shares of the company's stock, valued at approximately $20,922,509.35. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,792 shares of company stock worth $9,227,972. Corporate insiders own 5.63% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.